James M Mapes

US Patent:

7189516, Mar 13, 2007

Filed:

Aug 19, 2002

Appl. No.:

10/222867

Inventors:

James P. Mapes - Austin TX, US
James W. Jacobson - Austin TX, US
Harold N. Baker - Austin TX, US
Michael D. Spain - Austin TX, US

Assignee:

Luminex Corporation - Austin TX

International Classification:

G01N 33/53

US Classification:

435 71, 435 792, 435973, 436506, 436518, 436523, 436524

Abstract:

The invention relates to methods of characterizing autoimmune diseases by detecting and measuring at least one analyte using multiplexed assay systems. According to one embodiment, a target is detected and measured by different bead sets having different reactants. According to another approach the ratio of self-antigen to autoantibody is measured by exposing a sample suspected of containing self-antigen and autoantibody to a bead set associated with monoclonal antibody specific for the self-antigen and a bead set associated with the self-antigen.

US Patent:

7455980, Nov 25, 2008

Filed:

Feb 13, 2007

Appl. No.:

11/674365

Inventors:

James P. Mapes - Austin TX, US
James W. Jacobson - Austin TX, US
Harold N. Baker - Austin TX, US
Michael D. Spain - Austin TX, US

Assignee:

Luminex Corporation - Austin TX

International Classification:

G01N 33/53

US Classification:

435 71, 435 792, 435 794, 436501, 436518, 436523, 436811

Abstract:

The invention relates to methods of characterizing autoimmune diseases by detecting and measuring at least one analyte using multiplexed assay systems. According to one embodiment, a target is detected and measured by different bead sets having different reactants. According to another approach the ratio of self-antigen to autoantibody is measured by exposing a sample suspected of containing self-antigen and autoantibody to a bead set associated with monoclonal antibody specific for the self-antigen and a bead set associated with the self-antigen.

US Patent:

20050079099, Apr 14, 2005

Filed:

Oct 12, 2004

Appl. No.:

10/961145

Inventors:

Michael Spain - Austin TX, US
Craig Benson - Austin TX, US
Mark Chandler - Austin TX, US
James Mapes - Austin TX, US
Ralph McDade - Austin TX, US

Assignee:

Rules-Based Medicine, Inc. - Austin TX

International Classification:

G01N033/48

US Classification:

422072000, 436063000

Abstract:

A biochemical image is derived from specimens, preferably obtained from a statistically relevant sample of a subject population sharing a common characteristic. The biochemical images for one or more conditions present in the subject population and/or one or more test subjects are determined and made available for computer implemented diagnostic evaluations and medical research. In addition to using the information for general research purposes, information from the images may be used to classify diseases and disease states.

US Patent:

20070003981, Jan 4, 2007

Filed:

Jun 27, 2006

Appl. No.:

11/475249

Inventors:

Mark Chandler - Austin TX, US
Michael Spain - Austin TX, US
James Mapes - Austin TX, US
George Rodgers - Austin TX, US

International Classification:

G01N 33/53
C12Q 1/37

US Classification:

435007100, 435023000

Abstract:

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

US Patent:

20080255766, Oct 16, 2008

Filed:

Feb 7, 2008

Appl. No.:

12/068518

Inventors:

Michael Spain - Austin TX, US
James P. Mapes - Austin TX, US
Ralph L. McDade - Austin TX, US
Kenneth Pass - Glenmont NY, US

International Classification:

G01N 33/53
C12Q 1/00

US Classification:

702 19, 435 4, 435 71

Abstract:

Provided are methods for the detection and diagnosis of sickle cell. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of sickle cell. At least two new biomarkers for sickle cell are thus disclosed, Eotaxin and Monocyte Chemotactic Protein-1. Altogether the concentrations of eleven analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from sickle cell. Other important biomarkers for sickle cell are described, including but not limited to IL-12p40, SHBG, MMP-9, Adiponectin, Haptoglobin, FGF basic, IgM, Growth Hormone, Factor VII. Kits containing reagents to assist in the analysis of fluid samples are also described.

US Patent:

20080261253, Oct 23, 2008

Filed:

Jan 11, 2008

Appl. No.:

12/007500

Inventors:

Michael Spain - Austin TX, US
James P. Mapes - Austin TX, US
Ralph McDade - Austin TX, US
Kenneth Pass - Glenmont NY, US

International Classification:

G01N 33/543

US Classification:

435 794

Abstract:

Provided are methods for the detection and diagnosis of galactosemia. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of galactosemia. At least two new biomarkers for galactosemia are thus disclosed, Eotaxin and MCP-1. Altogether the concentrations these markers, individually, or in combinations with any of Alpha-2 Macroglobulin, Apolipoprotein H, Cancer Antigen 125, Leptin, TNF RII, Alpha-Fetoprotein, IgM, MIP-1 alpha, Ferritin, and IgE provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering from galactosemia. Kits containing reagents to assist in the analysis of fluid samples are also described.

US Patent:

20090068680, Mar 12, 2009

Filed:

Nov 18, 2008

Appl. No.:

12/273292

Inventors:

James P. Mapes - Austin TX, US
James W. Jacobson - Austin TX, US
Harold N. Baker - Austin TX, US
Michael D. Spain - Austin TX, US

Assignee:

LUMINEX CORPORATION - Austin TX

International Classification:

G01N 33/53

US Classification:

435 71

Abstract:

Methods for characterizing immune diseases are provided which include exposing a sample of biological fluid from a patient to a pooled population of particles, wherein a first subset of particles is bound to a reactant that binds an antibody and a second subset of particles is bound to a reactant that binds an antigen. The methods further include determining a ratio of measured amounts of the antibody and the antigen in the sample. In some cases, the ratio is compared to one or more standard ratios representing differing states of the disease to determine a state of the disease within the patient. In other embodiments, the steps of exposing and determining a ratio of antibody to antigen are repeated for one or more additional samples of biological fluid taken from the patient. In such cases, at least two ratios are compared to analyze a progression of the disease.

US Patent:

20090215077, Aug 27, 2009

Filed:

Apr 2, 2009

Appl. No.:

12/417496

Inventors:

Mark B. CHANDLER - Austin TX, US
Michael D. SPAIN - Austin TX, US
James MAPES - Austin TX, US
George RODGERS - Austin TX, US

International Classification:

G01N 33/53
C12Q 1/00
C12Q 1/48

US Classification:

435 71, 435 4, 435 15

Abstract:

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL--beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.